Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts

A. Tósaki, Dipak K. Das

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cromakalim, an adenosine triphosphate-sensitive potassium channel opener, shows proarrhythmic activity at moderate doses (1-10 μmol/liter) in the reperfused myocardium. We studied the effects of extracellular Mg++ ([Mg++](o)) on the incidence of reperfusion-induced ventricular fibrillator and ventricular tachycardia in isolated working hearts (n = 12 in each group) subjected to 20 min of global ischemia followed by 30 min of reperfusion, a modeling eliciting a low incidence of reperfusion arrhythmias, obtained from 8-wk streptozotocin-induced diabetic rats. Cromakalim, at a concentration of 3 μmol/liter, perfused 5 min before the induction of ischemia and throughout reperfusion increased the incidence off ventricular tachycardia from their drug-free diabetic control values of 25 an 42% ([Mg++](o) = 1.2 mmol/liter to 92% (P++](o) to 2.4, 3.6 and 4.8 mmol/liter in the perfusion buffer, the arrythmogenic effect of cromakalim was also abolished. Thus, with 2.4, 3.6 and 4.8 mmol/liter of [Mg++](o) perfused before the administration of cromakalim and the onset of ischemia, the incidence of reperfusion-induced ventricular tachycardia was reduced from 92% (in cromakalim treated group) to 67%, 42% (P++](o) prevented the cromakalim- induced cellular Na+ gain and K+ loss, measured by atomic absorption spectrophotometer. [Mg++](o) could prevent the proarrhythmic activity of cromakalim, and the use of cromakalim as an antihypertensive or antiischemic agent may be of particular concern in the population of postischemic diabetic subjects who are known to be at high risk of sudden coronary death.

Original languageEnglish
Pages (from-to)309-317
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume282
Issue number1
Publication statusPublished - Jul 1997

Fingerprint

Cromakalim
Reperfusion
Ventricular Tachycardia
Ischemia
Incidence
Potassium Channels
Streptozocin
Sudden Death
Antihypertensive Agents
Cardiac Arrhythmias
Myocardium
Buffers
Perfusion
Adenosine Triphosphate

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{466ad93b98af431996d6a129ff760d02,
title = "Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts",
abstract = "Cromakalim, an adenosine triphosphate-sensitive potassium channel opener, shows proarrhythmic activity at moderate doses (1-10 μmol/liter) in the reperfused myocardium. We studied the effects of extracellular Mg++ ([Mg++](o)) on the incidence of reperfusion-induced ventricular fibrillator and ventricular tachycardia in isolated working hearts (n = 12 in each group) subjected to 20 min of global ischemia followed by 30 min of reperfusion, a modeling eliciting a low incidence of reperfusion arrhythmias, obtained from 8-wk streptozotocin-induced diabetic rats. Cromakalim, at a concentration of 3 μmol/liter, perfused 5 min before the induction of ischemia and throughout reperfusion increased the incidence off ventricular tachycardia from their drug-free diabetic control values of 25 an 42{\%} ([Mg++](o) = 1.2 mmol/liter to 92{\%} (P++](o) to 2.4, 3.6 and 4.8 mmol/liter in the perfusion buffer, the arrythmogenic effect of cromakalim was also abolished. Thus, with 2.4, 3.6 and 4.8 mmol/liter of [Mg++](o) perfused before the administration of cromakalim and the onset of ischemia, the incidence of reperfusion-induced ventricular tachycardia was reduced from 92{\%} (in cromakalim treated group) to 67{\%}, 42{\%} (P++](o) prevented the cromakalim- induced cellular Na+ gain and K+ loss, measured by atomic absorption spectrophotometer. [Mg++](o) could prevent the proarrhythmic activity of cromakalim, and the use of cromakalim as an antihypertensive or antiischemic agent may be of particular concern in the population of postischemic diabetic subjects who are known to be at high risk of sudden coronary death.",
author = "A. T{\'o}saki and Das, {Dipak K.}",
year = "1997",
month = "7",
language = "English",
volume = "282",
pages = "309--317",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts

AU - Tósaki, A.

AU - Das, Dipak K.

PY - 1997/7

Y1 - 1997/7

N2 - Cromakalim, an adenosine triphosphate-sensitive potassium channel opener, shows proarrhythmic activity at moderate doses (1-10 μmol/liter) in the reperfused myocardium. We studied the effects of extracellular Mg++ ([Mg++](o)) on the incidence of reperfusion-induced ventricular fibrillator and ventricular tachycardia in isolated working hearts (n = 12 in each group) subjected to 20 min of global ischemia followed by 30 min of reperfusion, a modeling eliciting a low incidence of reperfusion arrhythmias, obtained from 8-wk streptozotocin-induced diabetic rats. Cromakalim, at a concentration of 3 μmol/liter, perfused 5 min before the induction of ischemia and throughout reperfusion increased the incidence off ventricular tachycardia from their drug-free diabetic control values of 25 an 42% ([Mg++](o) = 1.2 mmol/liter to 92% (P++](o) to 2.4, 3.6 and 4.8 mmol/liter in the perfusion buffer, the arrythmogenic effect of cromakalim was also abolished. Thus, with 2.4, 3.6 and 4.8 mmol/liter of [Mg++](o) perfused before the administration of cromakalim and the onset of ischemia, the incidence of reperfusion-induced ventricular tachycardia was reduced from 92% (in cromakalim treated group) to 67%, 42% (P++](o) prevented the cromakalim- induced cellular Na+ gain and K+ loss, measured by atomic absorption spectrophotometer. [Mg++](o) could prevent the proarrhythmic activity of cromakalim, and the use of cromakalim as an antihypertensive or antiischemic agent may be of particular concern in the population of postischemic diabetic subjects who are known to be at high risk of sudden coronary death.

AB - Cromakalim, an adenosine triphosphate-sensitive potassium channel opener, shows proarrhythmic activity at moderate doses (1-10 μmol/liter) in the reperfused myocardium. We studied the effects of extracellular Mg++ ([Mg++](o)) on the incidence of reperfusion-induced ventricular fibrillator and ventricular tachycardia in isolated working hearts (n = 12 in each group) subjected to 20 min of global ischemia followed by 30 min of reperfusion, a modeling eliciting a low incidence of reperfusion arrhythmias, obtained from 8-wk streptozotocin-induced diabetic rats. Cromakalim, at a concentration of 3 μmol/liter, perfused 5 min before the induction of ischemia and throughout reperfusion increased the incidence off ventricular tachycardia from their drug-free diabetic control values of 25 an 42% ([Mg++](o) = 1.2 mmol/liter to 92% (P++](o) to 2.4, 3.6 and 4.8 mmol/liter in the perfusion buffer, the arrythmogenic effect of cromakalim was also abolished. Thus, with 2.4, 3.6 and 4.8 mmol/liter of [Mg++](o) perfused before the administration of cromakalim and the onset of ischemia, the incidence of reperfusion-induced ventricular tachycardia was reduced from 92% (in cromakalim treated group) to 67%, 42% (P++](o) prevented the cromakalim- induced cellular Na+ gain and K+ loss, measured by atomic absorption spectrophotometer. [Mg++](o) could prevent the proarrhythmic activity of cromakalim, and the use of cromakalim as an antihypertensive or antiischemic agent may be of particular concern in the population of postischemic diabetic subjects who are known to be at high risk of sudden coronary death.

UR - http://www.scopus.com/inward/record.url?scp=0030847488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030847488&partnerID=8YFLogxK

M3 - Article

C2 - 9223569

AN - SCOPUS:0030847488

VL - 282

SP - 309

EP - 317

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -